Isoptin

Verapamil Hydrochloride, the active ingredient in Isoptin, is a calcium channel blocker presented as an intravenous solution for intravenous use. It treats hypertension, angina pectoris, atrial fibrillation and supraventricular tachycardia in adult patients.

GNH USA supplies Isoptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Isoptin (verapamil hydrochloride) is used to manage cardiovascular conditions that involve abnormal cardiac rhythm or elevated vascular resistance.

Hypertension: lowers blood pressure by decreasing peripheral vascular resistance. Angina pectoris: relieves chest pain by reducing myocardial oxygen demand. Atrial fibrillation: controls ventricular rate by slowing atrioventricular conduction. Supraventricular tachycardia: terminates tachycardic episodes by reducing conduction velocity.

Adverse reactions may occur with intravenous verapamil administration.

Common Side Effects: - Headache: mild to moderate headache may develop. - Flushing: transient warmth and redness of the skin. - Dizziness: light‑headed sensation, especially on standing. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Bradycardia or heart block: markedly slowed heart rate or conduction block. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

Careful monitoring is required when using Isoptin intravenously. - Monitor blood pressure: watch for excessive hypotension. - Monitor heart rate and ECG: detect bradycardia or AV block. - Use cautiously in heart failure: may worsen contractility. - Avoid in severe hepatic impairment: altered metabolism. - Adjust in renal impairment: consider accumulation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Verapamil can interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Beta‑blockers: additive negative chronotropic effect. - Digoxin: increased risk of atrioventricular block. - CYP3A4 inhibitors (e.g., ketoconazole): elevated verapamil plasma levels.

Moderate Interactions (Monitor Closely): - Other calcium channel blockers (e.g., diltiazem): additive hypotension. - NSAIDs: may reduce antihypertensive efficacy.